60 Degrees Pharmaceuticals, Inc. (SXTP)Healthcare | Biotechnology | Washington, United States | NasdaqCM
1.03 USD
-0.03
(-2.830%) ⇩
(Aug. 28, 2026, 4 p.m.
EDT)
After hours: 1.02 -0.01 (-0.010%) ⇩ (Aug. 28, 2026, 7:25 p.m. EDT) |
Hot Take ↕ | Aug. 22, 2026, 1:49 a.m. EDT
The investment case here is fundamentally broken. The business is hemorrhaging value with a -32.5% drop in revenue, gross margins of -96%, and massive negative free cash flow, indicating the company is burning through capital without generating sales. The price action confirms this deterioration, having lost 98.5% of its value over the last two years with two consecutive years of double-digit declines. While there is some recent buying pressure and a 'Buy' recommendation from analysts, these are likely driven by speculative warrants or private placements rather than genuine operational recovery, given the negative book value and deteriorating fundamentals. There is no dividend to provide any income cushion. This is a deep value trap where the market has correctly priced out the business model. |
| Model | MAE |
|---|---|
| AutoARIMA ✓ | 0.213323 |
| AutoETS | 0.216711 |
| AutoTheta | 0.218457 |
| MSTL | 0.223916 |
Forecast horizon: 45 days | Selected: AutoARIMA
| Forecast Reliability | |
|---|---|
| Score | 32% |
| H-stat | 31.60 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.098 |
| Excess Kurtosis | -1.57 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 5.979 |
| Revenue per Share | 0.762 |
| Market Cap | 3,622,497 |
| Forward P/E | -0.29 |
| Beta | 2.54 |
| Website | https://www.60degreespharma.com |
| Attribute | Value |
|---|---|
| 52 Week Change | -0.8133803 |
| Address1 | 1,025 Connecticut Avenue NW |
| Address2 | Suite 1000 |
| All Time High | 2,076.0 |
| All Time Low | 1.01 |
| Ask | 1.36 |
| Ask Size | 2 |
| Average Analyst Rating | 2.0 - Buy |
| Average Daily Volume10 Day | 58,880 |
| Average Daily Volume3 Month | 106,709 |
| Average Volume | 106,709 |
| Average Volume10Days | 58,880 |
| Beta | 2.541 |
| Bid | 0.7776 |
| Bid Size | 2 |
| Book Value | -2.615 |
| City | Washington |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 1.03 |
| Current Ratio | 2.325 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,786,665,600 |
| Day High | 1.12 |
| Day Low | 1.01 |
| Debt To Equity | 5.979 |
| Display Name | 60 Degrees Pharmaceuticals |
| Earnings Timestamp End | 1,755,025,200 |
| Earnings Timestamp Start | 1,755,025,200 |
| Ebitda | -8,504,303 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -1.438 |
| Enterprise To Revenue | 10.069 |
| Enterprise Value | 12,232,748 |
| Eps Current Year | -3.45 |
| Eps Forward | -3.58 |
| Eps Trailing Twelve Months | -2.59 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 1.4039 |
| Fifty Day Average Change | -0.37390006 |
| Fifty Day Average Change Percent | -0.26632956 |
| Fifty Two Week Change Percent | -81.33803 |
| Fifty Two Week High | 8.62 |
| Fifty Two Week High Change | -7.59 |
| Fifty Two Week High Change Percent | -0.88051045 |
| Fifty Two Week Low | 1.01 |
| Fifty Two Week Low Change | 0.01999998 |
| Fifty Two Week Low Change Percent | 0.019801961 |
| Fifty Two Week Range | 1.01 - 8.62 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,689,168,600,000 |
| Float Shares | 2,438,152 |
| Forward Eps | -3.58 |
| Forward P E | -0.2877095 |
| Free Cashflow | -6,081,180 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 3 |
| Fullday Change | -0.03 |
| Fullday Change Percent | -2.83019 |
| Fullday Price | 1.02 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | -1.6987 |
| Gross Profits | -2,063,804 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.19391 |
| Held Percent Institutions | 0.17111 |
| Implied Shares Outstanding | 3,516,988 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ipo Expected Date | 2,023-07-12 |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,768,867,200 |
| Last Split Factor | 1:4 |
| Long Business Summary | 60 Degrees Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases in the United States. It offers Arakoda for malaria prevention treatment. The company also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19 indications; Tafenoquine, which is in phase IIA clinical trials for babesiosis, fungal and pneumocystis pneumonias, and candidiasis disease; and Celgosivir for Zika, respiratory viruses, and dengue fever. It also has patent license agreement with Tufts Medical Center to jointly advance the development and commercialization of tafenoquine for the treatment and prevention of babesiosis. 60 Degrees Pharmaceuticals, Inc. was founded in 2010 and is headquartered in Washington, District Of Columbia. |
| Long Name | 60 Degrees Pharmaceuticals, Inc. |
| Market | us_market |
| Market Cap | 3,622,497 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_241910140 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | -8,624,435 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 3,728,007 |
| Number Of Analyst Opinions | 1 |
| Open | 1.09 |
| Operating Cashflow | -8,774,808 |
| Operating Margins | -10.92412 |
| Payout Ratio | 0.0 |
| Phone | 202 327 5422 |
| Post Market Change | -0.00999999 |
| Post Market Change Percent | -0.9708729 |
| Post Market Price | 1.02 |
| Post Market Time | 1,787,959,526 |
| Previous Close | 1.06 |
| Price Eps Current Year | -0.29855072 |
| Price Hint | 4 |
| Price To Book | -0.39388144 |
| Price To Sales Trailing12 Months | 2.9816484 |
| Profit Margins | 0.0 |
| Quick Ratio | 0.99 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | buy |
| Recommendation Mean | 2.0 |
| Region | US |
| Regular Market Change | -0.03 |
| Regular Market Change Percent | -2.83019 |
| Regular Market Day High | 1.12 |
| Regular Market Day Low | 1.01 |
| Regular Market Day Range | 1.01 - 1.12 |
| Regular Market Open | 1.09 |
| Regular Market Previous Close | 1.06 |
| Regular Market Price | 1.03 |
| Regular Market Time | 1,787,947,200 |
| Regular Market Volume | 22,172 |
| Return On Assets | -1.27108 |
| Return On Equity | -3.32853 |
| Revenue Growth | -0.325 |
| Revenue Per Share | 0.762 |
| Sand P52 Week Change | 0.20504117 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 3,516,988 |
| Shares Percent Shares Out | 0.0788 |
| Shares Short | 277,184 |
| Shares Short Previous Month Date | 1,784,073,600 |
| Shares Short Prior Month | 146,408 |
| Short Name | 60 Degrees Pharmaceuticals, Inc |
| Short Percent Of Float | 0.0793 |
| Short Ratio | 2.68 |
| Source Interval | 15 |
| State | DC |
| Symbol | SXTP |
| Target High Price | 3.7 |
| Target Low Price | 3.7 |
| Target Mean Price | 3.7 |
| Target Median Price | 3.7 |
| Total Cash | 1,022,606 |
| Total Cash Per Share | 0.291 |
| Total Debt | 151,179 |
| Total Revenue | 1,214,931 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -2.59 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 2.306775 |
| Two Hundred Day Average Change | -1.2767751 |
| Two Hundred Day Average Change Percent | -0.5534892 |
| Type Disp | Equity |
| Volume | 22,172 |
| Website | https://www.60degreespharma.com |
| Zip | 20,036 |